Search

Your search keyword '"Mambu Momoh"' showing total 4 results
Start Over Author "Mambu Momoh" Publisher nature portfolio
4 results on '"Mambu Momoh"'

1. Predicting the evolution of the Lassa virus endemic area and population at risk over the next decades

Author

Raphaëlle Klitting, Liana E. Kafetzopoulou, Wim Thiery, Gytis Dudas, Sophie Gryseels, Anjali Kotamarthi, Bram Vrancken, Karthik Gangavarapu, Mambu Momoh, John Demby Sandi, Augustine Goba, Foday Alhasan, Donald S. Grant, Sylvanus Okogbenin, Ephraim Ogbaini-Emovo, Robert F. Garry, Allison R. Smither, Mark Zeller, Matthias G. Pauthner, Michelle McGraw, Laura D. Hughes, Sophie Duraffour, Stephan Günther, Marc A. Suchard, Philippe Lemey, Kristian G. Andersen, and Simon Dellicour

Subjects
Science
Abstract

It is currently unknown how climate and land use changes could affect the endemic area of Lassa virus, a zoonotic pathogen responsible for Lassa fever. Here, the authors show that by 2070, new regions in Africa will likely become ecologically suitable for Lassa virus, drastically increasing the population living in conditions favourable for virus circulation.

Published
2022
Full Text
View/download PDF

2. Deployable CRISPR-Cas13a diagnostic tools to detect and report Ebola and Lassa virus cases in real-time

Author

Kayla G. Barnes, Anna E. Lachenauer, Adam Nitido, Sameed Siddiqui, Robin Gross, Brett Beitzel, Katherine J. Siddle, Catherine A. Freije, Bonnie Dighero-Kemp, Samar B. Mehta, Amber Carter, Jessica Uwanibe, Fehintola Ajogbasile, Testimony Olumade, Ikponmwosa Odia, John Demby Sandi, Mambu Momoh, Hayden C. Metsky, Chloe K. Boehm, Aaron E. Lin, Molly Kemball, Daniel J. Park, Luis Branco, Matt Boisen, Brian Sullivan, Mihret F. Amare, Abdulwasiu B. Tiamiyu, Zahra F. Parker, Michael Iroezindu, Donald S. Grant, Kayvon Modjarrad, Cameron Myhrvold, Robert F. Garry, Gustavo Palacios, Lisa E. Hensley, Stephen F. Schaffner, Christian T. Happi, Andres Colubri, and Pardis C. Sabeti

Subjects
Science
Abstract

Outbreaks of viral hemorrhagic fevers highlight the need for sensitive, field-deployable diagnostics. Here the authors present a CRISPR-based SHERLOCK platform with field protocol and mobile app for Ebola and Lassa fever outbreaks.

Published
2020
Full Text
View/download PDF

3. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits

Author

James E. Robinson, Kathryn M. Hastie, Robert W. Cross, Rachael E. Yenni, Deborah H. Elliott, Julie A. Rouelle, Chandrika B. Kannadka, Ashley A. Smira, Courtney E. Garry, Benjamin T. Bradley, Haini Yu, Jeffrey G. Shaffer, Matt L. Boisen, Jessica N. Hartnett, Michelle A. Zandonatti, Megan M. Rowland, Megan L. Heinrich, Luis Martínez-Sobrido, Benson Cheng, Juan C. de la Torre, Kristian G. Andersen, Augustine Goba, Mambu Momoh, Mohamed Fullah, Michael Gbakie, Lansana Kanneh, Veronica J. Koroma, Richard Fonnie, Simbirie C. Jalloh, Brima Kargbo, Mohamed A. Vandi, Momoh Gbetuwa, Odia Ikponmwosa, Danny A. Asogun, Peter O. Okokhere, Onikepe A. Follarin, John S. Schieffelin, Kelly R. Pitts, Joan B. Geisbert, Peter C. Kulakoski, Russell B. Wilson, Christian T. Happi, Pardis C. Sabeti, Sahr M. Gevao, S. Humarr Khan, Donald S. Grant, Thomas W. Geisbert, Erica Ollmann Saphire, Luis M. Branco, and Robert F. Garry

Subjects
Science
Abstract

Lassa virus can cause haemorrhagic fever for which no specific treatment currently exists. Here the authors have cloned 113 monoclonal antibodies from the survivors of Lassa infection and show that the majority of neutralizing antibodies target a complex of GP1 and GP2 viral proteins.

Published
2016
Full Text
View/download PDF

4. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits

Author

Robert W. Cross, Matthew L. Boisen, Mambu Momoh, Megan L. Heinrich, Michelle Zandonatti, Michael Gbakie, Joan B. Geisbert, Simbirie Jalloh, Juan Carlos de la Torre, Chandrika B. Kannadka, Momoh Gbetuwa, Julie A. Rouelle, Onikepe A. Follarin, S. Humarr Khan, Ashley A. Smira, Mohamed Fullah, Benjamin T. Bradley, Richard Fonnie, Kathryn M. Hastie, Luis M. Branco, Russell B. Wilson, Veronica J. Koroma, Danny Asogun, Mohamed A. Vandi, Christian T. Happi, Megan M. Rowland, Benson Yee Hin Cheng, Robert F. Garry, Deborah H. Elliott, Augustine Goba, Pardis C. Sabeti, Kristian G. Andersen, Brima Kargbo, Jeffrey G. Shaffer, James E. Robinson, Peter C. Kulakoski, Kelly R. Pitts, Thomas W. Geisbert, Luis Martinez-Sobrido, Donald S. Grant, Erica Ollmann Saphire, Peter O Okokhere, Odia Ikponmwosa, Lansana Kanneh, Courtney E Garry, Jessica N. Hartnett, John S. Schieffelin, Rachael E. Yenni, Sahr M. Gevao, and Haini Yu

Subjects
0301 basic medicine, Models, Molecular, medicine.drug_class, viruses, Science, General Physics and Astronomy, Cross Reactions, Monoclonal antibody, medicine.disease_cause, Antibodies, Viral, General Biochemistry, Genetics and Molecular Biology, Epitope, Article, 03 medical and health sciences, Epitopes, Lassa Fever, Viral Envelope Proteins, Glycoprotein complex, Antibody Specificity, medicine, Humans, Lassa fever, Lassa virus, Antigens, Viral, Sequence Deletion, chemistry.chemical_classification, Multidisciplinary, biology, Antibodies, Monoclonal, virus diseases, General Chemistry, Arenavirus, medicine.disease, Virology, Antibodies, Neutralizing, 3. Good health, 030104 developmental biology, Epitope mapping, chemistry, biology.protein, Mutagenesis, Site-Directed, Antibody, Glycoprotein, Epitope Mapping
Abstract

Lassa fever is a severe multisystem disease that often has haemorrhagic manifestations. The epitopes of the Lassa virus (LASV) surface glycoproteins recognized by naturally infected human hosts have not been identified or characterized. Here we have cloned 113 human monoclonal antibodies (mAbs) specific for LASV glycoproteins from memory B cells of Lassa fever survivors from West Africa. One-half bind the GP2 fusion subunit, one-fourth recognize the GP1 receptor-binding subunit and the remaining fourth are specific for the assembled glycoprotein complex, requiring both GP1 and GP2 subunits for recognition. Notably, of the 16 mAbs that neutralize LASV, 13 require the assembled glycoprotein complex for binding, while the remaining 3 require GP1 only. Compared with non-neutralizing mAbs, neutralizing mAbs have higher binding affinities and greater divergence from germline progenitors. Some mAbs potently neutralize all four LASV lineages. These insights from LASV human mAb characterization will guide strategies for immunotherapeutic development and vaccine design., Lassa virus can cause haemorrhagic fever for which no specific treatment currently exists. Here the authors have cloned 113 monoclonal antibodies from the survivors of Lassa infection and show that the majority of neutralizing antibodies target a complex of GP1 and GP2 viral proteins.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results